W. Zhang

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

Syma Iqbal, Bryan Goldman, Cecilia M. Fenoglio‐Preiser et al. · Annals of Oncology · 2011 · 160 citations · Full text

Medicine, Oncology, Pharmacology +17

Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab

W. Zhang, Michael S. Gordon, Anne M. Schultheis et al. · Journal of Clinical Oncology · 2006 · 20 citations

Medicine, Oncology, Pharmacology +16

Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)

Anthony B. El-Khoueiry, A. Pohl, Kathleen D. Danenberg et al. · Journal of Clinical Oncology · 2009 · 12 citations

Medicine, Oncology, Pharmacology +17

Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225)

W. Zhang, Jeong H. Yun, Oliver W. Press et al. · Journal of Clinical Oncology · 2004 · 10 citations

Medicine, Oncology, Pharmacology +17